The North America Pneumonia Vaccines Market would witness market growth of 3.7% CAGR during the forecast period (2019-2025). Pneumococcal disease is an infection which is caused by the Streptococcus pneumoniae bacteria, also called pneumococcus. Pneumococcal diseases range from mild to very severe. When the bacteria spread from the nose and throat to ears or sinuses, it causes mild infections. When it further spreads into other parts of the body, it leads to severe health problems like pneumonia, bacteremia, and meningitis. These ailments are often deadly, especially for adults 65 years or older, people with chronic health conditions, and individuals whose immune systems are weakened by disease or medicines (immunocompromised). The diseases also lead to disabilities like brain damage, deafness, or loss of arms or legs.
Every year in the United States, pneumonia kills thousands of adults. Many more adults end up in the hospital due to this disease. It can cause severe infections of the lungs (pneumonia), bloodstream (bacteremia), and lining of the brain and spinal cord (meningitis). Vaccines like PCV13 are the best solution which protects against 13 strains of pneumococcal bacteria and PPSV23 protects against 23 strains of pneumococcal bacteria. Both the vaccines ensure protection from illnesses like meningitis and bacteremia.
Based on Vaccine Type, the market is segmented into Pneumococcal conjugate vaccine (PCV) and Pneumococcal polysaccharide vaccine (PPSV/PPV). Based on Product Type, the market is segmented into Prevnar 13, Synflorix and Pneumovax23. According to sector, the market is segmented into Public sector and Private sector. Based on Distribution Channel, the market is further segmented into Distribution partner companies, Non-governmental Organizations (NGO) and Government Authorities. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
Market Segmentation:
By Vaccine Type
By Product Type
By Sector
By Distribution Channel
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 